ArticleJournal of Alzheimer's disease : JAD2026
Plasma lipid trajectories improve prediction of future Alzheimer's disease.
Article in Journal of Alzheimer's disease : JAD, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
BackgroundEarly identification of individuals at elevated risk for Alzheimer's disease (AD) is critical for prevention. Blood-based biomarkers offer scalable alternatives to cerebrospinal fluid and imaging, but the prognostic value of longitudinal plasma lipid trajectories remains unclear.ObjectiveTo evaluate whether multi-year plasma lipid trajectories improve prediction of AD conversion beyond demographic, clinical, genetic, and neuropsychological measures.MethodsWe studied 1150 cognitively normal or mildly impaired Alzheimer's Disease Neuroimaging Initiative participants; 329 progressed to AD dementia over a mean follow-up of 2.3 years. Plasma lipidomics quantified 749 lipid species by high-resolution LC-MS. Trajectories were summarized using functional principal component analysis and related to time to conversion using covariate-adjusted Cox proportional hazards models. Predictive performance was assessed by concordance index and likelihood-ratio tests.ResultsCross-sectional lipid profiles modestly improved prediction beyond demographic and clinical covariates, and longitudinal lipid trajectories yielded small additional gains. Ether-linked triglycerides showed the strongest longitudinal associations with conversion, with TG(O-50:1) [NL-18:1] exhibiting the most robust signal. Neuropsychological measures provided substantially stronger discrimination, and lipid trajectories added limited value once cognitive information was included. Nevertheless, longitudinal lipid changes contributed consistent improvements in models without neuropsychological predictors, supporting their role as complementary blood-based markers in settings where standardized cognitive assessments are unavailable or impractical.ConclusionsPlasma lipid trajectories capture biologically relevant metabolic change associated with AD progression and provide complementary predictive information. Longitudinal lipidomic profiling may support early risk stratification and cohort enrichment when cognitive assessments are unavailable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.